Overview
Using a collective impact approach for surveillance of drug overdoses to inform targeted drug-related prevention, treatment, policy-making, and harm reduction strategies is a core focus of work at the AMA.
The AMA is working to advance a public health approach to surveillance that can inform targeted drug-related prevention, treatment, and policy-making, as well as harm reduction strategies.
The AMA urges additional policy changes to accurately track overdose and mortality trends to provide equitable public health interventions that include comprehensive, disaggregated, racial and ethnic data collection related to testing, hospitalization, and mortality associated with opioids and other substances.
Shift from Response to Prevention
Collective Impact of Stakeholders
Each stakeholder plays an important role in the fight to end the drug overdose epidemic, but when stakeholders collaborate, the impact is far greater. This is true for preventative and treatment measures, policies surrounding overdoses, and surveillance efforts.
Resources
AMA prescription drug monitoring program national survey
Physicians and other authorized users queried state prescription drug monitoring programs (PDMPs) more than 910,000,000 times in 2020; more than double compared to 2018.
Organized Medicine’s Role in Strengthening a Public Health Approach to Overdose Morbidity and Mortality
AMA President, Susan R. Bailey, MD and the AMA Director of Science and Drug Policy, Amy B. Cadwallader, PhD presented a session at the 2021 Rx Drug Abuse & Heroin Summit that highlighted the reasons why data standardization and public health interventions have been elusive and they provide actionable solutions for states, organizations, and policymakers to meaningfully address the nation’s overdose epidemic.
Reports of efforts to help the nation’s overdose epidemic
Updated November 12, 2021. This issue brief is focused on positive interventions from 40 states that are working to help increase access to evidence-based treatment for substance use disorders, patients with pain and harm reduction efforts. The reports include news releases, data from multiple and varied sources, including national, state and local public health agencies, advocacy organizations, law enforcement, emergency medical services, hospitals, treatment centers, research journals and others.
America’s drug overdose epidemic: Select 2020-2021 research
Updated November 12, 2021 This issue brief is focused on providing a representative sample of the research published during the COVID-19 pandemic focused on substance use disorders, pain and harm reduction. It includes research from medical and scientific journals as well as advocacy organizations. Some of the materials require a subscription while most are publicly available.